Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2004

Chae S-, Paik J-, Allende ML, Proia RL, Hla T. Regulation of limb development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the hypoxia/VEGF axis. Dev Biol. 2004;268(2):441-7.

Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19(2):114-20.

Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004;64(24):8867-75.

De Cecco L, Marchionni L, Gariboldi M, Reid JF, M Lagonigro S, Caramuta S, et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 2004;23(49):8171-83.

2003

Magro CM, Klinger DM, Adams PW, Orosz CG, Pope-Harman AL, W Waldman J, et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant. 2003;3(10):1264-72.

Kahana DD, Cass O, Jessurun J, Schwarzenberg SJ, Sharp H, Khan K. Sclerosing cholangitis associated with trichosporon infection and natural killer cell deficiency in an 8-year-old girl:. J Pediatr Gastroenterol Nutr. 2003;37(5):620-3.

Cannon M, Philpott NJ, Cesarman E. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol. 2003;77(1):57-67.

Bubman D, Cesarman E. Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin North Am. 2003;17(3):717-45.

Chadburn A, Narayanan S. Lymphoid malignancies: immunophenotypic analysis. Adv Clin Chem. 2003;37:293-353.

Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep. 2003;4(3):307-12.